Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029643 | 0.85 | ALDH1A1 (0.55) | KMT2AMAPTHTTALDH1A1HPGD | |
| SCHEMBL2755845 | 0.83 | MAPT (0.54) | KMT2AMAPTHTTALDH1A1HPGD | |
| SCHEMBL20560676 | 0.83 | MAPT (0.54) | KMT2AMAPTHTTALDH1A1HPGD | |
| SCHEMBL19462541 | 0.83 | HDAC1 (0.73) | KMT2AMAPTHTTALDH1A1HPGD | |
| SCHEMBL30748254 | 0.82 | SMN1; SMN2 (0.55) | KMT2AMAPTHTTALDH1A1PKM | |
| SCHEMBL8955980 | 0.82 | SMN1; SMN2 (0.55) | KMT2AMAPTHTTALDH1A1PKM | |
| SCHEMBL19456057 | 0.81 | ALDH1A1 (0.49) | KMT2AMAPTHTTALDH1A1HPGD | |
| SCHEMBL4799944 | 0.81 | HDAC1 (0.57) | KMT2AMAPTKDM4ELMNAMEN1 | |
| SCHEMBL8419703 | 0.80 | MAPT (0.58) | KMT2AMAPTHTTALDH1A1HPGD | |
| SCHEMBL21624307 | 0.80 | MAPT (0.51) | KMT2AMAPTHTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310373-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2023-10-05 | — | — | US | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| EP-3164509-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3164509-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-113024466-A | Tetra-substituted olefin compound and use thereof | 卫材 R&D 管理有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-107847498-B | Tetra-substituted olefin compound and use thereof | 卫材R&D管理有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-106604997-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| CN-1377337-A | Process for preparation of phenylacetic acid derivatives | NOVARTIS AG (CH) | 2002-10-30 | — | — | CN | disclosed |
| EP-0727421-A1 | Agents for improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-08-21 | — | — | EP | disclosed |
| US-5302390-A | ADMINISTERING TO TREAT THROMBOTIC DISEASES | BEECHAM GROUP PLC (GB) | 1994-04-12 | — | — | US | disclosed |
| EP-0297882-B1 | HYBRID PLASMINOGEN ACTIVATORS | BEECHAM GROUP PLC (GB) | 1993-08-25 | — | — | EP | disclosed |
| EP-0297882-A2 | Hybrid plasminogen activators | BEECHAM GROUP PLC (GB) | 1989-01-04 | — | — | EP | disclosed |
| EP-0285219-A2 | Method of improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-10-05 | — | — | EP | disclosed |
| EP-0009487-B1 | NEW DERIVATES FROM BENZAMIDE | DEBIOPHARM S.A. (CH) | 1984-05-02 | — | — | EP | disclosed |
| US-4312862-A | Therapeutically active derivatives of benzamide | DEBIOPHARM SA (CH) | 1982-01-26 | — | — | US | disclosed |
| EP-0009487-A1 | NEW DERIVATES FROM BENZAMIDE. | DEBIOPHARM SA (CH) | 1980-04-16 | — | — | EP | disclosed |
| WO-1979000517-A1 | NEW DERIVATES FROM BENZAMIDE | APPLIFARM SA (CH) | 1979-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | BRCA1, ESR2, ESR1 | KMT2A 3295/4885MAPT 3047/4885HTT 3626/4885 |
| US-20230310373-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | CTSC, CTSG, CTSZ | KMT2A 1717/4885MAPT 4410/4885HTT 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.